All Stories

  1. Cytotoxic Microspinosamides from the Marine Sponge Geodia microspinosa That Decrease Diffuse Pleural Mesothelioma Viability

    Article • Marine Drugs, September 2026, MDPI AG

    Dr. Vivek Singh

  2. Circulating Proteomic Signatures for Multicancer Early Detection: Cross-Platform Evidence for a Matrix–Immune–Secretory Biomarker Axis

    Article • Journal of Proteome Research, August 2026, American Chemical Society (ACS)

    Dr. Vivek Singh

  3. Therapeutic targeting of DNA repair pathway dysregulation in aging, cancer, and neurodegeneration

    Article • Expert Opinion on Therapeutic Targets, June 2026, Taylor & Francis

    Dr. Vivek Singh

  4. SLD5/GINS4 controls dynein-dependent centrosome maturation and exposes a candidate mitotic vulnerability in cancer

    Article • May 2026, openRxiv

    Dr. Vivek Singh

  5. L7. Identification of Novel Immune Modulators for Mesothelioma Therapy

    Article • Journal of Thoracic and Cardiovascular Surgery, May 2026, Elsevier

    Dr. Vivek Singh

  6. XRRA1 acts as a molecular brake on radiation-induced DNA damage signaling and immunogenic cell death in tumor cells

    Article • April 2026, openRxiv

    Dr. Vivek Singh

  7. Abstract 2064: miR-1293 suppresses diffuse pleural mesothelioma growth by targeting a novel S100A16-Hippo-EMT axis.

    Article • Cancer Research, April 2026, American Association for Cancer Research (AACR)

    Dr. Vivek Singh

  8. Role of IGF2BP3 as a prognostic biomarker in chronic myeloid leukemia progression and disease stratification

    Article • Current Research in Translational Medicine, April 2026, Elsevier

    Dr. Vivek Singh

  9. Cellular autophagy and aging: role in intermittent fasting-induced health benefits

    Article • January 2026, Elsevier

    Dr. Vivek Singh

  10. Decoding the Circulating Proteome: Matrix and Immune Context Markers Shape Early Multi-Cancer Detection

    Article • November 2025, Cold Spring Harbor Laboratory Press

    Dr. Vivek Singh

  11. Next-generation leukemia diagnostics: Integrating LC-MS/MS proteomics with liquid biopsy platforms

    Article • The Journal of Liquid Biopsy, September 2025, Elsevier

    Dr. Vivek Singh

  12. microRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesothelioma

    Article • Molecular Therapy — Nucleic Acids, September 2025, Elsevier

    Dr. Vivek Singh

  13. Identification of Cembrane Diterpenoids from Sinularia sp. That Reduce the Viability of Diffuse Pleural Mesothelioma Cell Lines

    Article • Journal of Natural Products, August 2025, American Chemical Society (ACS)

    Dr. Vivek Singh

  14. Comprehensive Analysis of Oncogenic Determinants across Tumor Types via Multi-Omics Integration

    Article • Cancer Genetics, August 2025, Elsevier

    Dr. Vivek Singh

  15. Inflammation-Driven Tumorigenesis: Mechanisms, Immune Evasion, and Therapeutic Strategies

    Article • International Journal of Clinical and Translational Medicine, July 2025, Australia Academic Press Pty Ltd

    Dr. Vivek Singh

  16. Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential

    Article • Journal of Experimental & Clinical Cancer Research, March 2025, Springer Science + Business Media

    Dr. Vivek Singh

  17. AI-Powered Exploration of IGF2BP3 as a Prognostic Biomarker in Chronic Myeloid Leukemia Progression and Disease Stratification

    Article • January 2025, Cold Spring Harbor Laboratory Press

    Dr. Vivek Singh

  18. Advancements in High-Performance Liquid Chromatography: Transforming Analytical Chemistry Across Biomedical, Pharmaceutical, and Environmental Domains

    Article • January 2025, Springer Science + Business Media

    Dr. Vivek Singh

  19. Unravelling Neuroinflammation-Mediated Mitochondrial Dysfunction in Mild Cognitive Impairment: Insights from Targeted Metabolomics

    Article • Brain Organoid and Systems Neuroscience Journal, October 2024, Elsevier

    Dr. Vivek Singh, Dr Dinesh Kumar

  20. Targeting HIF-1α in sickle cell disease and cancer: unraveling therapeutic opportunities and risks

    Article • Expert Opinion on Therapeutic Targets, June 2024, Taylor & Francis

    Dr. Vivek Singh

  21. Exploring novel protein biomarkers for early-stage diagnosis and prognosis of T-acute lymphoblastic leukemia (T-ALL)

    Article • Hematology Transfusion and Cell Therapy, March 2024, Elsevier

    Dr. Vivek Singh

  22. Expression of CXCL8 (IL-8) in the Pathogenesis of T-Cell Acute Lymphoblastic Leukemia Patients

    Article • Cureus, September 2023, Springer Science + Business Media

    Dr. Vivek Singh

  23. The Molecular Role of HIF1α Is Elucidated in Chronic Myeloid Leukemia

    Article • Frontiers in Oncology, June 2022, Frontiers

    Dr. Vivek Singh

  24. The bioengineered HALOA complex induces anoikis in chronic myeloid leukemia cells by targeting the BCR-ABL/Notch/Ikaros/Redox/Inflammation axis

    Article • Journal of Medicine and Life, May 2022, Fundatia Jurnalului Journal of Medicine and Life

    Dr. Vivek Singh

  25. Formulation and biophysical characterization of SNARE’s like the behavior of human α-lactalbumin oleic acid (HALOA) complex as an anticancerous agent against chronic myeloid leukemia.

    Article • March 2022, Authorea, Inc.

    Dr. Vivek Singh

  26. Role of interleukin-8 as a molecular indicator in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL)

    Article • March 2022, Research Square

    Dr. Vivek Singh

  27. HALOA a new biotherapeutic agent against CML.

    Article • Journal of Medicine and Life, January 2021, Fundatia Jurnalului Journal of Medicine and Life

    Dr. Vivek Singh, Dr Dinesh Kumar

  28. Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation

    Article • Inflammation, May 2020, Springer Science + Business Media

    Dr. Vivek Singh